Rive B
Johnson & Johnson , ,
ArticleKetamine
ECHO: Results from a Non-Interventional Cohort Study of Esketamine Nasal Spray in Treatment Resistant Depression
ArticleKetamine
Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD.
ArticleKetamine
Improvements in Functioning with Esketamine Nasal Spray versus Quetiapine Extended Release in Patients with Treatment Resistant Depression
ArticleKetamine
Outcomes with esketamine nasal spray in patients with or without earlier partial or full response: post hoc analyses of ESCAPE TRD
ArticleKetamine
Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression.
ArticleKetamine
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial - ERRATUM.
ArticleKetamine
Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.
ArticleKetamine
Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.
ArticleKetamine
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.
ArticleKetamine